Arrayus announces Health Canada approval of its focused ultrasound therapy system

Arrayus Technologies Inc., a leader in innovative medical technology, recently announced that its MRI-guided focused ultrasound system has been granted approval by Health Canada for the ablation of uterine fibroid tissue. Following the success of its first-in-human clinical trial, this approval paves the way for Canadian healthcare providers to offer a safe, non-invasive alternative to traditional surgical options for this common gynecological condition.

Arrayus' focused ultrasound system, offers a transformative approach to non-invasive therapy, using high-precision acoustic energy to target and treat tissue deep within the body without the need for incisions or general anesthesia.

Arrayus is actively expanding the potential applications for its focused ultrasound platform. The company has clinical trials underway to evaluate the use of its system in various oncological settings, and is working with healthcare professionals, researchers, and industry partners to explore its use in neurology, women's health, and beyond. 

Arrayus Technologies is an alumnus of the HealthMINT™, CAAP® and WiHI programs, and presented at the OBIO® Investment Summit.